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Wedge Resection for Non-small Cell Lung Cancer in
Patients with Pulmonary Insufficiency: Prospective
Ten-Year Survival
John P. Griffin, MD,* Charles E. Eastridge, MD,†‡ Elizabeth A. Tolley, PhD,§
and James W. Pate, MD
Background: Possibility of curative resection by lobectomy for
non–small cell lung cancer is often denied patients with compro-
mised pulmonary reserve. Analysis of survival of such patients treated
by wedge resection was compared with that of patients treated by
standard resection, with both groups followed for 10 years.
Design: A prospective 5-year cohort study.
Methods: From 1988 to 1992, an observational cohort of 127
consecutive resected patients at Memphis VA Medical Center was
divided into those receiving lobectomy in 81 cases and pneumonec-
tomy in 15 cases (group I) versus 31 patients with compromised
pulmonary reserve (group II), who had complete tumor excision by
wedge resection. Preoperative clinical staging was corrected to
surgical–pathological staging after demonstration of its superiority.
Survival estimates were obtained by Kaplan–Meier method with
curves compared by log rank tests, with all-cause mortality calcu-
lated from date of surgery.
Results: Extent of disease in group I was 58% stage I, 19% stage II,
and 23% stage III. In group II, extent of disease was 84% stage I, 3%
stage II, and 14% stage III. Group I median survival was 26 months
with 30% 5-year survival; for group II, median survival was 30
months and 32%. Kaplan–Meier survival plots showed similar
curves in groups I and II. Realizing less extent of disease in group
II, another Kaplan–Meier plot restricted to stage I and II patients
showed overlapping survival curves for groups I and II.
Conclusion: Survival during 10-year observation was similar for
patients with pulmonary insufficiency treated by wedge resection to
that of patients receiving standard resection in this single-institution
consecutive cohort.
Key Words: Lung cancer, Surgery, Diagnosis and staging, Statis-
tics, Survival analysis, Lung physiology, Lung pathology.
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Complete surgical excision remains the greatest potentialcurative therapy for patients with non-small cell lung
cancer (NSCLC). Of the American Cancer Society’s 2004
estimate of 173,700 cases of newly diagnosed bronchogenic
carcinoma, complete resection could only be performed in
approximately 20% of patients, which presumably influenced
the 160,440 deaths from this disease expected that year1 and
the overall 5-year survival rate of about 15%. A high inci-
dence of “poor–surgical-risk” patients (with “poor surgical
risk” based on comorbidity factors such as COPD and cardiac
disease) contributes to these unfortunate results. Although
many thoracic surgeons had previously favored limited re-
section in such patients by segmentectomy2,3 or wedge exci-
sion,4 the randomized study conducted by the Lung Cancer
Study Group (LCSG)5 was considered by many to have
established lobectomy as the standard minimal operation for
this disease, based on reported mortality and recurrence rates.
As Shields6,7 pointed out in 1989, adequate local resection is
not analogous to “incomplete resection,” in which gross or
microscopic tumor is left in situ.
More aggressive attempts to perform lobectomy in
individuals with marginal pulmonary physiologic reserve led
to evaluation of cardiopulmonary exercise studies as well as
simpler dynamic testing, such as stair climbing,8 to discrim-
inate between high- and low-risk patients for surgical resec-
tion. An alternative proposal in the present investigation
examined the feasibility of grossly complete wedge resection
for patients who would otherwise be denied the opportunity
for surgical treatment.9 In 1988, our VA hospital’s decentral-
ized computer program permitted single-institution evalua-
tion of survival in a 5-year cohort of patients with NSCLC,
22% of whom received thoracotomy for a similar number of
adenocarcinomas and squamous cell tumors of stage I and II
clinical extent.10 The goal of this study was to determine
whether equivalent crude survival rates could be achieved using
wedge resection for patients with poor pulmonary reserve com-
pared with those achieved using standard lobectomy/pneumo-
nectomy in patients without physiologic compromise.
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METHODS
A prospective observational cohort of 127 consecutive
patients, all male, had resection of NSCLC by the same
surgeon (C.E.E.) at Memphis VA Medical Center from 1988
through 1992. By design, this cohort was divided into two
subcohorts according to type of resection and respiratory
reserve status, which were completely confounded. When
cardiac abnormalities were identified by usual clinical find-
ings, cardiology consultation was obtained for clearance for
general anesthesia and thoracotomy prior to entry into this
prospective investigation. Group I patients received standard
lobectomy in 81 instances and pneumonectomy in 15 in-
stances. Group II consisted of 31 other patients who were
considered at increased risk for standard resection because of
poor physiologic respiratory reserve, based on either static
pulmonary function testing demonstrating FEV 12 liters or
dynamic measurement of lack of three-flight stair-climbing
ability11,12 to qualify for lobectomy. At surgery, the tumor
was identified by palpation and completely resected with
several millimeters of adjacent normal tissue, usually with
staplers, and sometimes with multiple clamp and suture
technique; frozen sections were taken of any marginal areas
that appeared suspicious, and further local excisions were
done until all margins were “clear.” Anatomic segmental
resection was rarely used, and no thoracoscopic resections
were done. Formal lymphadenectomy was not performed, but
lymph nodes in the hilum, subcarina, and paratracheal medi-
astinum were evaluated by visualization and palpation, and
grossly abnormal nodes were removed for pathological
evaluation. When no abnormal nodes were found, random
sampling of nodes in each of these areas was done for
staging purposes. Prospective patient allocation during the
1988 to 1992 study period required use of the 1986
international clinical staging system of Mountain,13 but
because of the increased accuracy of pathological staging
demonstrated in the 1997 revision of the international
system,14,15 review and modification of staging in both
patient groups was subsequently performed. All patients
were followed by the authors until their demise, at 3-month
intervals the first year, at 6-month intervals the second
year, and annually thereafter for the 10-year period. Con-
current usual thoracic surgical and pulmonary medical care
were provided patients in both treatment groups, including
palliative radiotherapy, chemotherapy, and supportive measures
as indicated.
The primary end point of this study was a comparison
of all-cause mortality in the two subcohorts, and no second-
ary end points, such as tumor recurrence rates or comorbidi-
ties, were proposed. Survival estimates of both groups were
obtained by the Kaplan–Meier16 method, and the survival
curves were compared with log rank tests, which included
those patients experiencing 30-day surgical mortality. All-
cause mortality was calculated from the date of surgical
treatment until death. To determine whether survival rates of
the subcohorts were affected by confounding with staging,
data were further analyzed for only patients with stage I or II
extent of disease.
RESULTS
Table 1 portrays the distribution of cell types by technique
of resection, showing a minimal predominance of squamous cell
carcinomas in group I and adenocarcinomas in group II patients.
Table 2 shows the distribution of pathological staging by tech-
nique of resection, demonstrating after postsurgical staging a
predominance of more advanced disease in group I compared
with group II. Surgical mortality included five patients who died
within 30 days of their resection, all occurring in group I (three
lobectomy, two pneumonectomy).
Patients treated by wedge resection (group II) were an
average age of 69 years (52–87). Representative pulmonary
function studies in these men showed a mean FEV 1 of 1.4
liters (1.2–1.8), a mean FEV 1/FVC of 48% (42–60), and an
average MVV of 42% (20–55) of predicted. All patients who
were treated by the more limited resection had failed to
complete the required three-flight stair-climb test to qualify
for lobectomy. Mean diameter of resected adenocarcinomas
was 2.6 cm (1.5–7.0), and mean diameter of squamous cell
tumors was 2.8 cm (0.8–8.2). Radiation therapy was admin-
istered in an adjuvant mode in eight patients (26%) who
received wedge resection; only four patients (13%) received
chemotherapy, all for palliation. Although the primary end
point in this study was all-cause mortality, nine of these
patients (29%) were clinically free of lung cancer at the time
of their death from other causes.
Interestingly, 5- and 10-year crude survival cure rates
of the group I and II subcohorts were almost identical.
TABLE 1. Distribution of Cell Types by Technique of
Resection for a Consecutive Surgical Series of Patients with




Group I Group II
n % n %
Squamous 46 48 13 42
Adenocarcinoma 40 42 16 52
Large cell 6 6 1 3
Adenosquamous 3 3 1 3
Bronchioalveolar 1 1 0 0
Total 96 31
TABLE 2. Distribution of Pathological Staging by
Technique of Resection for a Consecutive Surgical Series of
Patients with Non-small Cell Lung Cancer From 1988 to
1992 at Memphis VA Medical Center
Resection
Stage
Group I Group II
n % n %
I 56 58 26 84
II 18 19 1 3
IIIA 16 17 2 7
IIIB 6 6 2 7
Total 96 31
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Twenty-nine patients (30%) who received lobectomy or
pneumonectomy lived for five more years, and 10 patients
(32%) who were treated by wedge resection reached this end
point. After 10 years, only 11% of group I patients, all of
whom had lobectomy, were alive, compared with 10% of
group II patients. Table 3 lists a median survival rate of 23
months for patients undergoing lobectomy or pneumonec-
tomy; for those who received the more limited resection,
median survival was 31 months. Figure 1 shows a Kaplan–
Meier plot demonstrating similar survival of patients in
groups I and II. Because of an excess of patients with more
advanced disease in the standard resection group, Table 4
depicts median survival rates only for patients with stage I or
stage II disease, showing 29 months for group I and 35
months for group II. Furthermore, Figure 2 compares a
Kaplan–Meier plot of patients in these two groups to include
only those with pathological stages I or II in extent; again, the
survival curves of both groups are remarkably similar. This
similarity of survival curves does not appear to be influenced
by surgical–pathological staging.
DISCUSSION
The LCSG5 collected data from a prospective multi-
center clinical trial with 276 patients, comparing lobectomy
with limited procedures such as segmentectomy or wedge
resection. After a 3-year follow-up, there was a higher local
recurrence rate with limited resection, and the LCSG5 stated
in 1995 that because of a lower death rate and fewer local–
regional recurrences, lobectomy was the minimal acceptable
operation for patients with stage I NSCLC. Using a permis-
sive alpha error of p  0.10, they described a significant
increase in total mortality and cancer-specific mortality in
patients receiving limited forms of resection. However, based
on absence of differences in selected variables between treat-
ment groups, only 247 of the 276 randomized patients were
analyzed, and when the entire population of patients was
compared in Kaplan–Meier survival plots, the difference
between treatment groups lost statistical significance. In an
attached editorial, Benfield17 stated that “data are insufficient
to support dogma about the superiority of lobectomy because
its main proven advantage over smaller resections is fewer
postoperative local recurrences . . . if the goal of resection is
to prevent death due to systemic cancer, the LCSG results
could be interpreted as having failed to show that lobectomy
is better than limited resection.”
Prior to the LCSG5 randomized study, others had rec-
ommended local resection rather than lobectomy in poor-risk
patients. In 1972, Le Roux2 reported 17 patients whose small
peripheral bronchial carcinomas were managed by segmen-
tectomy, with a survival rate no worse than that after more
extensive resections. Two years later, Shields and Higgins,18
in a report for the VA Surgical Group on more than 3000
patients undergoing thoracotomy for treatment of lung can-
FIGURE 1. Kaplan–Meier plot for a consecutive surgically
resected series of patients with non-small cell lung cancer
from 1988 to 1992 at Memphis VA Medical Center, based
on all-cause mortality.
TABLE 3. Survival Estimates (months) for a Consecutive
Surgically Resected Series of Patients with Non-small Cell
Lung Cancer From 1988 to 1992 at Memphis VA Medical
Center, Based on All-Cause Mortality
Median 25% 75% Mean Standard Error
Group I 23 9.5 66 45.1 5.1
Group II 31 14.0 76 47.0 7.5
TABLE 4. Survival Estimates (months) for a Consecutive
Surgically Resected Series of Patients with Pathological Stage
I or II Non-small Cell Lung Cancer From 1988 to 1992 at
Memphis VA Medical Center, Based on All-Cause Mortality
Median 25% 75% Mean Standard Error
Group I 29 14 74 53.4 6.2
Group II 35 22 77 52.0 8.2
FIGURE 2. Kaplan–Meier plot for a consecutive surgically
resected series of patients with pathological stage I or II non-
small cell lung cancer from 1988 to 1992 at Memphis VA
Medical Center, based on all-cause mortality.
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cer, found that limited resection in 40 high-risk patients
showed a 5-year survival rate of 28.5%. Jensik and col-
leagues19 published a continued favorable experience with
segmental resection for peripheral stage I lung cancer with a
53% 5-year survival rate in 168 patients. Jacobson et al.4
evaluated the safety of types of limited excision and favored
wedge resection, with 7% major complications versus 19%
with segmentectomy. In 1982 Peters20 stated that in patients
with insufficient pulmonary reserve, lobectomy cannot be the
procedure of choice for early-stage lung cancer, and that a
lesser resection is indicated. Errett and colleagues21 reported
100 patients who had intentional wedge resections for periph-
eral clinical stage I NSCLC, with actuarial survival rates at 2
years virtually identical between wedge and lobectomy
groups. Miller and Hatcher22 in 1987 reported on limited
resection of bronchogenic carcinoma for patients with
marked impairment of pulmonary function. Pastorino et al.,23
as well as Read and associates,24 studying survival after
limited resection for T1N0M0 NSCLC, stated that wedge
resection was the definitive treatment for very small periph-
eral primary lung tumors. Warren and Faber25 found similar
long-term survival for stage I NSCLC patients treated with
lobectomy or limited resection, but local recurrence was
greater after segmentectomy.
Since the report of the LCSG5 randomized study, con-
tinued interest in the role of limited resection for early stages
of NSCLC has been evident in the medical literature.26
Cerfolio and associates27 reported the Mayo Clinic experi-
ence in 1996 of 35 patients with compromised pulmonary
function who had local resection but yielded a 5-year survival
of 44%. Wedge resection versus lobectomy for stage I
NSCLC was also evaluated by Landreneau et al.,28 with 117
and 102 patients, respectively; the Kaplan–Meier survival
curves were nearly identical 1 year after surgery, and after 5
years, patients having wedge resection had a significantly
greater non–cancer-related death rate. Kodama and associ-
ates29 evaluated segmentectomy with lymph node dissection
for 46 patients with T1 N0 M0 NSCLC compared with 77
concurrent patients who received lobectomy; multivariate
analysis showed that limited resection was not associated
with decreased survival.
Okada et al.30 prospectively enrolled 70 patients with
NSCLC of 2 cm or smaller who were able to tolerate
lobectomy; the 5-year survival of patients with segmentec-
tomy was 87%, whereas a concurrent group of similar pa-
tients receiving lobectomy experienced an identical 5-year
survival rate.
The usual coexistence of COPD and major compromise
of pulmonary function indicates a need for conserving lung
parenchyma when feasible. Many patients with lung cancer
were so physiologically impaired that insistence on lobec-
tomy as a minimal acceptable resection would deny them the
opportunity of receiving the only possibly curative treatment.
Multiple synchronous and metachronous occurrences of pri-
mary NSCLC give further support to the need for conserva-
tive excision techniques so that multiple potentially curative
surgical resections might be possible.7 This prospective ob-
servational study of physiologically compromised patients
with NSCLC resected by the same surgeon (C.E.E.), in a
single institution and with follow-up of all patients for 10
years or until their demise, adds support to this concept.
CONCLUSION
This group of pulmonary physiologically compromised
patients who received complete wedge resection for NSCLC
had survival results during 10 years of follow-up and analysis
that were not statistically different from those “acceptable-
risk” patients who concurrently received lobectomy or pneu-
monectomy for resection of their lung cancer.
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